Testing Experimental Treatment for Multiple Myeloma
common.study.values.description
“A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma”
The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) and schedules for each combination (combination 1: daratumumab and JNJ-64407564 [anti-GPRC5DxCD3] or combination 2: daratumumab and JNJ-64007957 [anti-BCMAxCD3]) and to characterize the safety of each RP2D for each combination.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-yes
Drug - Daratumumab
Participants will receive daratumumab SC.
Drug - JNJ-64407564
Participants will receive JNJ-64407564 IV.
Drug - JNJ-64007957
Participants will receive JNJ-64007957 IV.
participant.views.study.view.additional
participant.views.study.view.scientific-title
A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Subjects With Multiple Myeloma
common.study.values.clinical-trial-id
NCT04108195
participant.views.study.view.id
e9rWxa
